Market conditions continue to evolve, and with ongoing uncertainty shaping investor sentiment, biotech CFOs are taking a more strategic and creative approach to capital deployment and value creation.

We will begin the program with a brief market and investor update from Biocom’s CEO, Tim Scott, reflecting insights from his recent delegation to China with fellow CEOs, including perspectives on global sentiment, partnership dynamics, and implications for biotech capital strategy.

From there, the conversation will shift into a fireside chat with Kat Lange, Chief Business Officer of Avidity Biosciences, exploring how finance leaders are navigating today’s environment and the evolving range of paths across the industry—from reverse mergers and PIPEs to strategic asset sales, spinouts, and other innovative transaction structures.

Together, we’ll unpack what’s working, what’s gaining traction, and how companies are positioning themselves for what’s ahead.

Agenda At-A-Glance

4 p.m. | Registration & Networking

4:30-4:45p.m. | Welcome Remarks & Tim Scott’s Update on China

4:45pm – 5:30 p.m. | Fireside Chat with Kat Lange

5:30pm-6:30pm | Networking Reception

6:30 p.m. | Event Concludes